<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	
	>
<channel>
	<title>
	Comments on: Deepmatter shares surge on AstraZeneca partnership	</title>
	<atom:link href="https://ukinvestor.foxrobinson.com/deepmatter-shares-surge-on-astrazeneca-partnership/feed/" rel="self" type="application/rss+xml" />
	<link>https://ukinvestor.foxrobinson.com/deepmatter-shares-surge-on-astrazeneca-partnership/</link>
	<description></description>
	<lastBuildDate>Mon, 27 Jan 2020 12:05:47 +0000</lastBuildDate>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.6.3</generator>
	<item>
		<title>
		By: AstraZeneca end trial for Epanova - UK Investor Magazine		</title>
		<link>https://ukinvestor.foxrobinson.com/deepmatter-shares-surge-on-astrazeneca-partnership/#comment-13572</link>

		<dc:creator><![CDATA[AstraZeneca end trial for Epanova - UK Investor Magazine]]></dc:creator>
		<pubDate>Mon, 13 Jan 2020 11:01:12 +0000</pubDate>
		<guid isPermaLink="false">https://ukinvestor.foxrobinson.com/?p=24919#comment-13572</guid>

					<description><![CDATA[[&#8230;] The firm had seen a very impressive few weeks of trading as they agreed a tie up deal with Deepmatter Group PLC (LON:DMTR) in a digital technology venture. [&#8230;]]]></description>
			<content:encoded><![CDATA[<p>[&#8230;] The firm had seen a very impressive few weeks of trading as they agreed a tie up deal with Deepmatter Group PLC (LON:DMTR) in a digital technology venture. [&#8230;]</p>
]]></content:encoded>
		
			</item>
		<item>
		<title>
		By: AstraZeneca sell two cancer drug rights for $198 million - UK Investor Magazine		</title>
		<link>https://ukinvestor.foxrobinson.com/deepmatter-shares-surge-on-astrazeneca-partnership/#comment-13343</link>

		<dc:creator><![CDATA[AstraZeneca sell two cancer drug rights for $198 million - UK Investor Magazine]]></dc:creator>
		<pubDate>Fri, 20 Dec 2019 14:26:46 +0000</pubDate>
		<guid isPermaLink="false">https://ukinvestor.foxrobinson.com/?p=24919#comment-13343</guid>

					<description><![CDATA[[&#8230;] joined forces with the FTSE 100 giant in a digital technology venture, designed to speed up the drug delivery [&#8230;]]]></description>
			<content:encoded><![CDATA[<p>[&#8230;] joined forces with the FTSE 100 giant in a digital technology venture, designed to speed up the drug delivery [&#8230;]</p>
]]></content:encoded>
		
			</item>
	</channel>
</rss>
